CD274 and melanoma: Increased CD8+ T-cell infiltration/proliferation, PD-1, PD-L1, granzyme B, and phosphorylated STAT1 positive immune cells in melanoma tumors have been observed by IHC or gene expression after treatment with pembrolizumab or nivolumab in other trials [50, 51].